Gritstone Oncology (NASDAQ:GRTS) and Erytech Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.
Valuation and Earnings
This table compares Gritstone Oncology and Erytech Pharma’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Gritstone Oncology||$1.19 million||290.25||-$64.78 million||($7.26)||-1.33|
|Erytech Pharma||N/A||N/A||-$45.14 million||$2.44||2.32|
Insider & Institutional Ownership
57.7% of Gritstone Oncology shares are held by institutional investors. Comparatively, 8.2% of Erytech Pharma shares are held by institutional investors. 38.0% of Gritstone Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Gritstone Oncology and Erytech Pharma, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Gritstone Oncology currently has a consensus price target of $21.33, indicating a potential upside of 120.61%. Given Gritstone Oncology’s higher possible upside, equities research analysts plainly believe Gritstone Oncology is more favorable than Erytech Pharma.
This table compares Gritstone Oncology and Erytech Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Gritstone Oncology beats Erytech Pharma on 5 of the 9 factors compared between the two stocks.
Gritstone Oncology Company Profile
Gritstone Oncology Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.
Erytech Pharma Company Profile
ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France.
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.